Oligonucleotide API Manufacturing
Oligonucleotide API manufacturing requires precise control of synthesis, downstream processing, purification, isolation, and analytical testing to consistently produce drug substances that meet predefined quality requirements. As oligonucleotide programs progress from preclinical studies to clinical and commercial development, manufacturing processes must be capable of supporting increasing production scales while maintaining product quality and batch-to-batch consistency. Protheragen provides Oligonucleotide API Manufacturing Services for the production of synthetic oligonucleotide drug substances across different development stages. Manufacturing activities can support process scale-up, GMP production, purification and isolation, analytical testing, batch release, and technology transfer according to project-specific requirements.
Overview of Oligonucleotide API Manufacturing
Oligonucleotide API manufacturing generally consists of a series of interconnected upstream and downstream operations. For synthetic oligonucleotides, the manufacturing process commonly includes solid-phase synthesis, cleavage and deprotection, purification, concentration or desalting, and API isolation. Lyophilization is frequently used to obtain a solid drug substance, although an oligonucleotide API may also be maintained in solution when supported by appropriate stability, concentration, microbiological control, packaging, and storage considerations.
The manufacturing process must account for the characteristics of the oligonucleotide sequence, backbone chemistry, nucleotide modifications, synthesis scale, impurity profile, and intended dosage form. Product-related impurities such as truncated sequences, deletion sequences, insertion sequences, modified species, and degradation products can arise during synthesis and downstream processing and therefore require appropriate process and analytical controls.
Manufacturing operations are supported by in-process controls and analytical testing to monitor identity, purity, molecular characteristics, impurities, residual materials, and other relevant quality attributes. Process controls, equipment suitability, material controls, environmental conditions, and batch documentation are progressively aligned with the development stage and applicable GMP requirements.
Fig.1 Broad categories of biomolecular engineering strategies and considerations for the process design and API/DP attributes of resultant structures. (Ebrahimi SB, et al., 2024)
Our Services
Oligonucleotide API manufacturing encompasses multiple operations that work together to produce consistent and well-characterized drug substance batches. Key services cover synthesis, downstream purification and isolation, scale-up manufacturing, analytical testing, GMP production, and manufacturing support.
Oligonucleotide API Manufacturing
Oligonucleotide API manufacturing follows established manufacturing processes and quality systems for clinical and late-stage drug substance production. Manufacturing activities focus on process consistency, documentation, in-process controls, and batch quality.
Services include:
- Oligonucleotide API production
- Batch manufacturing and documentation
- In-process quality control
- Manufacturing process monitoring
- Clinical-stage drug substance supply
Oligonucleotide Synthesis Manufacturing
Solid-phase oligonucleotide synthesis assembles target sequences through controlled nucleotide addition cycles. Manufacturing controls focus on coupling efficiency, synthesis consistency, impurity formation, and overall process yield.
Services include:
- Solid-phase oligonucleotide synthesis
- Nucleotide coupling and capping
- Phosphodiester or phosphorothioate synthesis
- Modified oligonucleotide synthesis
- Synthesis cycle control
Cleavage and Deprotection
Controlled cleavage and deprotection release the synthesized oligonucleotide from the solid support and remove protecting groups. The process maintains product integrity while controlling degradation and unwanted chemical reactions.
Services include:
- Solid-support cleavage
- Nucleobase deprotection
- Backbone deprotection
- Global deprotection
- Crude oligonucleotide preparation
Purification and Impurity Removal
Purification removes truncated sequences, deletion products, modified oligonucleotides, residual reagents, and other process-related impurities. Controlled purification improves API purity while maintaining product recovery.
Services include:
- Preparative oligonucleotide purification
- Chromatographic separation
- Truncated sequence removal
- Related impurity clearance
- Purified API fraction collection
Concentration and Desalting
Concentration and desalting remove salts, solvents, buffers, and other low-molecular-weight components from purified oligonucleotide solutions. The process prepares the API for final isolation or downstream drug product manufacturing.
Services include:
- Ultrafiltration and diafiltration
- Desalting
- Buffer exchange
- API concentration
- Purified oligonucleotide solution processing
API Isolation and Lyophilization
API isolation converts purified oligonucleotide into the required drug substance form. Lyophilization produces a solid API with controlled moisture content and suitable storage and handling characteristics.
Services include:
- Oligonucleotide API isolation
- Precipitation and solid recovery
- Lyophilization
- Drying process control
- Solid API preparation
Scale-Up and Clinical Supply Manufacturing
Scale-up manufacturing transfers established processes from development scale to larger production scales for preclinical and clinical supply. Manufacturing activities focus on process consistency, production yield, purification capacity, and batch reproducibility.
Services include:
- Laboratory-to-pilot scale-up
- Pilot-scale API manufacturing
- Clinical supply production
- Process scale-up
- Manufacturing batch production
Batch Testing and Release Support
Batch testing evaluates the identity, purity, assay, molecular characteristics, impurities, and other defined quality attributes of manufactured API. Analytical results and manufacturing records support quality review and batch release.
Services include:
- API identity testing
- Purity and related substance analysis
- Assay and concentration testing
- Molecular weight characterization
- Residual solvent and impurity testing
- Batch release testing
Oligonucleotide API Manufacturing Process
Oligonucleotide API Manufacturing Quality Control
| Quality Attribute |
Typical Analytical Focus |
| Identity |
Confirmation of oligonucleotide identity and sequence |
| Purity |
Main component purity and related substances |
| Assay |
Quantitative determination of API content |
| Molecular Weight |
Confirmation of expected molecular mass |
| Sequence Integrity |
Assessment of sequence-related characteristics |
| Truncated / Failure Sequences |
Monitoring synthesis-related impurities |
| Residual Solvents |
Control of process-related solvents |
| Water Content |
Moisture determination |
| Counter-Ions / Elements |
Control of relevant inorganic components |
| Endotoxin |
Microbiological quality assessment |
| Bioburden |
Microbiological control where applicable |
| Other Product-Specific Attributes |
Testing based on molecular structure and specifications |
Analytical testing is selected according to the oligonucleotide modality, manufacturing process, quality specifications, and development stage.
Manufacturing Considerations for Oligonucleotide APIs
Product Quality
Oligonucleotide manufacturing must maintain control of identity, purity, molecular characteristics, impurities, and other relevant CQAs throughout the process.
Process Consistency
Consistent control of synthesis cycles, downstream purification, isolation, and drying is important for minimizing batch-to-batch variability.
Impurity Control
Impurity formation is closely related to synthesis efficiency and downstream processing. Appropriate process controls and purification strategies are therefore important for achieving the required API quality.
Yield and Recovery
Oligonucleotide manufacturing involves multiple unit operations, and product losses can occur during synthesis, purification, concentration, desalting, and isolation. Manufacturing processes are therefore designed to balance impurity clearance with overall product recovery.
Scalability
Manufacturing processes should be capable of transitioning from development scale to larger production scales without compromising product quality or process robustness.
Storage and Handling
The physical form, concentration, packaging, storage temperature, and handling conditions of the API are considered according to its stability profile and downstream drug product requirements.
Why Choose Protheragen
- Integrated Development-to-Manufacturing Support
Oligonucleotide API manufacturing can be connected with upstream process development, analytical development, drug product manufacturing, and stability studies within an integrated CMC workflow.
- Multiple Oligonucleotide Modalities
Manufacturing support can be adapted to ASOs, siRNAs, PMOs, CpG oligonucleotides, and other chemically modified oligonucleotide APIs.
- Flexible Manufacturing Scales
Manufacturing programs can be structured according to the requirements of preclinical, clinical, and later-stage development.
- GMP-Oriented Manufacturing
Manufacturing processes, documentation, quality controls, and analytical testing can be aligned with the applicable development stage and GMP requirements.
- Integrated Analytical and Quality Support
Analytical testing and quality control are incorporated into the manufacturing workflow to support process monitoring, batch evaluation, and API release.
- Technology Transfer Support
Process knowledge and manufacturing requirements can be transferred from development into production through a structured technology transfer process.
A robust oligonucleotide manufacturing strategy connects process understanding with reproducible production, analytical control, and quality management. From solid-phase synthesis and downstream purification to API isolation, GMP production, and clinical supply, each manufacturing stage contributes to the quality and consistency of the final drug substance. Protheragen supports the transition from oligonucleotide process development to API manufacturing, providing a continuous CMC pathway for oligonucleotide programs progressing toward clinical and commercial development. Contact us to discuss your oligonucleotide API manufacturing requirements and develop a manufacturing strategy aligned with your development stage, scale, and quality objectives.
Reference
- Ebrahimi SB, et al. "Engineering Considerations for Developing Next-Generation Oligonucleotide Therapeutics." Nat Chem Eng. 2024; 1(12):741-750.
